Clinical Study of Previously Untreated Patients With Malignant Melanoma

Phase 2 Completed 42 enrolled Clavis Pharma

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Previously untreated patients with malignant melanoma receive a new chemotherapy drug currently under development. CP-4055 is given intravenously on days 1-5 every four weeks until complete response or disease progression.

Timeline

Start: 2005-09
Primary completion: —
Completion: 2007-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Elacytarabine	Small molecule	200 mg/m2	Intravenous

Clinical Study of Previously Untreated Patients With Malignant Melanoma

Summary

Timeline

Drugs

Indications